slv-341

SLV-341 is a small molecule drug that acts as a modulator of cytoplasmic and nuclear receptors. It was initially developed by AbbVie and has also been associated with Genfit and Solvay Pharmaceuticals. The primary therapeutic area for SLV-341 is endocrinology and metabolic disease, with its main indication being type 2 diabetes mellitus. Its mechanism of action involves modulation of nuclear receptors, which are key regulators in metabolic pathways relevant to diabetes. Clinical development reached Phase 1, but the only registered clinical trial (NCT00887445) was terminated after investigating safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy male subjects[1][2][3].